Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aclaris Therapeutics Inc

ACRS
Current price
1.24 USD +0.01 USD (+0.81%)
Last closed 1.23 USD
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 85 819 256 USD
Yield for 12 month -86.49 %
1Y
3Y
5Y
10Y
15Y
ACRS
21.11.2021 - 28.11.2021

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 701 Lee Road, Wayne, PA, United States, 19087

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.8 USD

P/E ratio

Dividend Yield

Current Year

+31 249 000 USD

Last Year

+29 752 000 USD

Current Quarter

+17 570 000 USD

Last Quarter

+9 282 000 USD

Current Year

+13 168 000 USD

Last Year

+17 792 000 USD

Current Quarter

+11 142 000 USD

Last Quarter

+8 434 000 USD

Key Figures ACRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -117 565 000 USD
Operating Margin TTM -134.99 %
PE Ratio
Return On Assets TTM -32.53 %
PEG Ratio -0.13
Return On Equity TTM -49.88 %
Wall Street Target Price 1.8 USD
Revenue TTM 31 249 000 USD
Book Value 2.22 USD
Revenue Per Share TTM 0.45 USD
Dividend Share
Quarterly Revenue Growth YOY 126.6 %
Dividend Yield
Gross Profit TTM -60 021 000 USD
Earnings Share -1.27 USD
Diluted Eps TTM -1.27 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -283.15 %

Dividend Analytics ACRS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ACRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ACRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 35.3605
Price Sales TTM 2.7463
Enterprise Value EBITDA 0.2846
Price Book MRQ 0.546

Financials ACRS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ACRS

For 52 weeks

0.59 USD 11.12 USD
50 Day MA 1.21 USD
Shares Short Prior Month 5 122 089
200 Day MA 4.23 USD
Short Ratio 4.06
Shares Short 4 890 232
Short Percent 7.95 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics